Results 91 to 100 of about 3,401,781 (173)
Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel. [PDF]
Faramand R +25 more
europepmc +1 more source
Introduction Cytokine release syndrome (CRS) is a rare immune‐related adverse event of immune checkpoint inhibitors (ICIs). At present, its association with avelumab–axitinib therapy for renal cell carcinoma (RCC) has yet to be reported.
Hirokazu Kiuchi +15 more
core +1 more source
Chimeric antigen receptor (CAR)-T cell therapy holds significant potential for cancer treatment, although disease relapse and cytokine release syndrome (CRS) remain as frequent clinical challenges.
Daniela S Santurio +3 more
doaj +1 more source
Cytokine Release Syndrome Induced by Pembrolizumab for Metastatic Anal Melanoma
Cytokine release syndrome (CRS) is a rare systemic inflammatory response that can be triggered by certain drugs and infections, commonly diagnosed at a disseminated stage, leading to poor prognosis. This has been well described following chimeric antigen
Erica Martel +3 more
doaj +1 more source
CAR T cell–derived TNF is an early determinant of cytokine release syndrome severity
Cytokine release syndrome (CRS) is a common and potentially severe toxicity of chimeric antigen receptor (CAR) T cell therapy, characterized by activation of the host myeloid compartment and systemic inflammation.
Theodoros Giavridis +8 more
core +1 more source
Apoptotic Cells Dramatically Ameliorate the Efficacy of CAR T-Cell Therapy and Prevents Cytokine Release Syndrome (CRS) [PDF]
Dror Mevorach, Hila Hoizman
openaire +1 more source
Immune checkpoint inhibitors (ICIs) have gained widespread application in the treatment of malignant tumors. Cytokine release syndrome (CRS) is a systemic inflammatory response triggered by various factors, including infections and immunotherapy.
Xiuping Zhang +4 more
core +1 more source

